AAV-TBG-Cre-sgKmt2d
(Plasmid
#192164)
-
Purpose(Empty Backbone) AAV-TBG-Cre-sgKmt2d
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 192164 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepAAV
-
Vector typeAAV
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameNone
-
MutationNA
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
AAV-TBG-Cre-sgKmt2d was a gift from Sidi Chen (Addgene plasmid # 192164 ; http://n2t.net/addgene:192164 ; RRID:Addgene_192164) -
For your References section:
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade. Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, Du Y, Cheng Y, Niu L, Chu Z, Kim K, Liao C, Clark P, Errami Y, Chen S. Cancer Discov. 2020 Dec;10(12):1912-1933. doi: 10.1158/2159-8290.CD-19-1448. Epub 2020 Sep 4. 10.1158/2159-8290.CD-19-1448 PubMed 32887696